Jul 10,2023

Tandem Diabetes Care to Announce Second Quarter 2023 Financial Results on August 3, 2023

Tandem Diabetes Care will release Q2 2023 results on August 3, 2023. A conference call and webcast will discuss the financial and operating results. A webcast archive will be available for 30 days.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 11,2023

Tandem Mobi, World’s Smallest Durable Insulin Delivery System, Receives FDA Clearance

Tandem Diabetes Care receives FDA clearance for the Tandem Mobi insulin pump for diabetes patients aged 6 and above. The Mobi is the world's smallest durable automated insulin delivery system, controllable via a mobile app. It will be offered with Control-IQ technology, providing automated insulin delivery and other features. Limited release expected in late 2023, full commercial availability planned in early 2024.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 17,2023

North America Blood Glucose Monitoring Market Size & Share Analysis

The North American blood glucose monitoring market is expected to grow at a CAGR of over 8% due to increased diabetes cases linked to COVID-19, according to the publisher. Continuous Glucose Monitoring (CGM) holds a significant market share, and the United States is expected to dominate the market.

View Analyst & Ambassador Comments
Go to original news
Jul 19,2023

HealthTab™ to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

Avricore Health partners with Ascensia Diabetes Care to integrate CONTOUR®NEXT Blood Glucose Meters into HealthTab, enhancing diabetes patient insights and care in Canada. The partnership’s objective is to support patients and pharmacists in Canada in better managing diabetes by linking the daily blood glucose testing results and pattern history data collected via the CONTOUR®NEXT GEN or CONTOUR®NEXT ONE meter the patient uses to the patient’s HealthTab account. The partnership also seeks to support utilization of each technology by opening discussions related to collaborative communications to ensure patients and pharmacists are able to take advantage of what these data insights offer.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2023

Global Insulin Pens Market to Reach $16.8 Billion by 2030

The global insulin pens market is expected to reach $16.8 billion by 2030, with China leading growth at 13.6% CAGR, according to the publisher. Economic challenges persist due to inflation and geopolitical uncertainties.

View Analyst & Ambassador Comments
Go to original news
Jul 13,2023

Blood Glucose Monitoring System Market revenue to hit USD 46 Billion by 2033

The global blood glucose monitoring system market is expected to reach a revenue of USD 46 billion by 2033, with a projected CAGR of around 10% from 2023 to 2033, according to the publisher. Major players in the market include Abbott Laboratories, Roche, Dexcom, Medtronic, and Ascensia Diabetes Care.

View Analyst & Ambassador Comments
Go to original news
Jul 14,2023

Lark Health’s AI Coaching Drives Weight Loss Results in HPSAs

Lark Health conducted studies on their digital coaching programs, highlighting the positive outcomes in diabetes prevention. Their digital diabetes prevention program (DPP) reduced the risk of type 2 diabetes and promoted weight loss in underserved areas. Additionally, the program showed a decrease in depressive symptoms and improved engagement with the use of self-monitoring technologies.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 14,2023

Blood Glucose Monitoring Devices Market to Worth USD 23.15 Billion by 2030

The global blood glucose monitoring devices market is expected to reach USD 23.15 billion by 2030, with a CAGR of 8% from 2023 to 2030, according to the publisher. The market is segmented based on product, testing site, patient care setting, modality, application, and distribution channel. Key players include Roche, Sanofi, Dexcom, Abbott Laboratories, and Medtronic. North America dominates the market, while the Asia Pacific region shows the fastest growth.

View Analyst & Ambassador Comments
Go to original news
Jul 14,2023

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

Nemaura Medical reported financial results for the fiscal year ended March 31, 2023. They secured $8.4 million in funding, signed an agreement with Eversana, and achieved positive patient data in weight loss studies. The company aims to ramp up commercial sales and global partnerships. Research and development expenses were consistent with the prior year at approximately $1.5 millionwhile the company's cash and cash equivalents at 31st March 2023 were reported as approximately $10.1m

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Vida Health makes two additions to executive leadership team

Virtual cardiometabolic care leader Vida Health today announced the additions of Elaine Divelbliss and Andrew Webb to its executive leadership team. Divelbliss as Chief People Officer & General Counsel and Webb as Chief Financial Officer.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES